All In Biotech

Drug Trial Radar · NCT06193304

A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth

An Open-label Study to Assess the Absorption Through the Mouth After Three Repeated 50 mg Doses of Eliglustat Solution, Separated by 2-hour Intervals, Held in the Mouth for 30 Seconds With Swishing But Without Ingestion, in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jan 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Aug 25, 2014

Primary completion

Sep 21, 2014

Study completion Sep 21, 2014

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to assess the absorption of eliglustat through the mouth in healthy subjects and the safety of any systemic exposure resulting from oral surface absorption of eliglustat in healthy subjects.

Conditions

  • Gaucher's Disease

Interventions

  • EliglustatDrug

    Pharmaceutical form:solution -Route of administration: Oral wihtout ingestion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma pharmacokinetic (PK) parameter: CmaxTime frame: Multiple timepoints on Day 1
  2. Plasma pharmacokinetic (PK) parameter tmaxTime frame: Multiple timepoints on Day 1
  3. Plasma pharmacokinetic (PK) parameter AUClastTime frame: Multiple timepoints on Day 1
  4. Plasma pharmacokinetic (PK) parameter AUC 0-2hTime frame: Multiple timepoints on Day 1
  5. Plasma pharmacokinetic (PK) parameter AUC 2-4hTime frame: Multiple timepoints on Day 1
  6. Plasma pharmacokinetic (PK) parameter AUC 4-6hTime frame: Multiple timepoints on Day 1
  7. Plasma pharmacokinetic (PK) parameter tlastTime frame: Multiple timepoints on Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Researsh Unit

    Evansville, Indiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.